Castleview Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Castleview Partners’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-242	Closed	-$10.3K	–	589
2024 Q4	$10.3K	Hold	242	–	–	0.01%	575
2024 Q3	$10.7K	Hold	242	–	–	0.01%	536
2024 Q2	$9.63K	Hold	242	–	–	0.01%	534
2024 Q1	$10.4K	Hold	242	–	–	0.01%	537
2023 Q4	$10.1K	Hold	242	–	–	0.01%	512
2023 Q3	$9.62K	Hold	242	–	–	0.01%	431
2023 Q2	$9.92K	Hold	242	–	–	0.01%	434
2023 Q1	$9.92K	Hold	242	–	–	0.01%	425
2022 Q4	$9.91K	Hold	242	–	–	0.01%	372
2022 Q3	$10K	Buy	242 +238	+5,950%	+$10.2K	0.01%	385
2022 Q2	$174	Sell	4 -238	-98%	-$9.98K	﹤0.01%	744
2022 Q1	$10K	Buy	+242	New	+$10.6K	0.01%	503
2021 Q2	$13K	Buy	+242	New	+$12.2K	0.01%	642

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Castleview Partners's XPH Position: Q1 2025 in Review

Castleview Partners sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2025, closing a stake of 242 shares — an estimated $10.3K sold.

Castleview Partners first reported a position in XPH in Q2 2021 and held it in 13 quarters. The position peaked at $13K in Q2 2021. 70 funds tracked by Wall St. Rank hold XPH as of Q1 2025.

Castleview Partners reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2025 after selling out during the quarter.
Castleview Partners sold 242 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2025, an estimated $10.3K.
Castleview Partners first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2021 and held it in 13 quarters.
Castleview Partners's State Street SPDR S&P Pharmaceuticals ETF position peaked at $13K in Q2 2021.
70 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.